Browsing: Therapeutics

This is a paid press release. Contact the press release distributor directly with any inquiries.

Japanese startup Celaid Therapeutics Inc. has announced the completion of the second close of its Series B financing round. The round welcomed Shionogi & Co., Ltd. and Teikoku Ventures, Inc. as new investors, raising a total of JPY 400 million (approximately $2.6 million).

Aptadir Therapeutics, a biotech company developing a new class of RNA inhibitor-based therapies for the treatment of intractable genetic disorders, has announced that it has closed a seed funding round worth 40 million euros.

Calif., Sept. 25, 2026/PRNewswire/ –KaliTherapeutics, a clinical-stage biotechnology company pioneering next-generation immune-resetting and multi-specific therapies, today announced its selection as a winner of the 2026 Endpoints 11, the annual list of the 11 most promising private biotechnology companies curated by the Endpoints News editorial team

Up to $35 million from the Gates Foundation will support ProFound’s use of its platform, datasets, and algorithms to identify new drug targets and biomarkers for preeclampsia and eclampsia

Axsome Therapeutics (NASDAQ: AXSM), a biotech company, has performed fairly well this year. The company’s shares are up 16% versus the S&P 500’s 11%. Could the stock rise even higher? Wall Street certainly thinks so. Axsome Therapeutics’ average price target (according to Yahoo! Finance) of $285.42 implies about a 37% upside from its current level.…

Silence Therapeutics and AbCellera launched respective common share public offerings, and Beyang Therapeutics and Remepy closed $30+ million oversubscribed Series A rounds.

Second quarter 2026 net product revenue of $18.6 million; cash and cash equivalents of $219.1 million as of June 30, 2026

Beyang Therapeutics has raised nearly $30 million in an oversubscribed Series A financing round to advance its AI-powered drug discovery platform and clinical pipeline.